片仔癀PZH2113胶囊Ⅰ期临床试验完成首例受试者入组

Core Viewpoint - The company Pianzaihuang has initiated a Phase I clinical trial for its innovative drug PZH2113, targeting relapsed/refractory B-cell non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma, marking a significant step in providing new treatment options for patients [1] Group 1: Clinical Trial Details - The Phase I clinical trial is an open-label, multi-center study focusing on the safety, tolerability, pharmacokinetics, and preliminary efficacy of PZH2113 capsules [1] - The first subject has been enrolled in the trial, indicating the official commencement of the clinical study [1] Group 2: Market Context - PZH2113 is positioned as an innovative drug with the potential to offer new treatment alternatives for patients suffering from relapsed/refractory non-Hodgkin lymphoma [1] - As of the announcement date, there are no approved drugs with the same target indication available in the domestic and international markets [1]